Your browser doesn't support javascript.
loading
Probiotics Regulating Inflammation via NLRP3 Inflammasome Modulation: A Potential Therapeutic Approach for COVID-19.
Kasti, Arezina N; Synodinou, Kalliopi D; Pyrousis, Ioannis A; Nikolaki, Maroulla D; Triantafyllou, Konstantinos D.
Afiliação
  • Kasti AN; Department of Nutrition and Dietetics, Attikon University General Hospital, 12462 Athens, Greece.
  • Synodinou KD; Department of Nutrition and Dietetics, Attikon University General Hospital, 12462 Athens, Greece.
  • Pyrousis IA; Department of Nutrition and Dietetics, Attikon University General Hospital, 12462 Athens, Greece.
  • Nikolaki MD; Medical School, University of Patras, 26504 Patras, Greece.
  • Triantafyllou KD; Department of Nutrition and Dietetics, Attikon University General Hospital, 12462 Athens, Greece.
Microorganisms ; 9(11)2021 Nov 17.
Article em En | MEDLINE | ID: mdl-34835501
Inflammasomes are cytoplasmic multiprotein complexes formed by the host's immune system as a response to microbial infection and cellular damage. Many studies have revealed various regulators of NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome activation, while it has been recently shown that NLRP3 is implicated in COVID-19 pathogenesis. At the same time, probiotics counteract the inflammatory process and modulate cytokine release, thus influencing both innate and adaptive immune systems. Herein, we review the immunomodulatory potential of probiotics on the assembly of NLRP3 inflammasome, as well as the pathophysiological mechanisms supporting the use of probiotic bacteria for SARS-CoV-2 infection management, presenting evidence from preclinical studies of the last decade: in vivo, ex vivo, and mixed trials. Data show that probiotics intake is related to NLRP3 inflammasome attenuation and lower levels of inflammation markers, highlighting the beneficial effects of probiotics on inflammatory conditions. Currently, none of the ongoing clinical trials evaluating the effectiveness of probiotics intake in humans with COVID-19 has been completed. However, evidence from preclinical studies indicates that probiotics may block virus invasion and replication through their metabolites, bacteriocins, and their ability to block Angiotensin-Converting Enzyme 2 (ACE2), and by stimulating the immune response through NLRP3 inflammasome regulation. In this review, the beneficial effects of probiotics in the inflammatory process through NLRP3 inflammasome attenuation are presented. Furthermore, probiotics may target SARS-CoV-2 both by blocking virus invasion and replication and by stimulating the immune response through NLRP3 inflammasome regulation. Heterogeneity of the results-due to, among others, different bacterial strains and their metabolites, forms, dosage, and experimental designs-indicates the need for more extensive research.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Microorganisms Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Grécia

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Microorganisms Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Grécia